By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: n/a Fax: n/a



Company News
MabVax Therapeutics, Inc. Enters Agreements With Memorial Sloan-Kettering Cancer Center And Juno Therapeutics For Development Of Anti-Cancer Therapeutics 9/10/2014 8:14:07 AM
Fresh From Co-Founding Massively Financed Juno Therapeutics, Arch Venture Partners Banks $400 Million+ To Back New Biotechs 8/27/2014 5:58:54 AM
Already-Rich Juno Therapeutics Reels In Another $134 Million, Has Raised $300 Million In Less Than 12 Months 8/5/2014 6:17:28 AM
Cancer-Fighter Juno Therapeutics Completes $176 Million Series A Round 4/24/2014 6:28:49 AM
Clinical Trial Of Juno Therapeutics Cell Therapy Restarts 4/21/2014 7:36:27 AM
Seattle's Juno Therapeutics Pauses Trial After Patient Deaths 4/9/2014 7:07:21 AM
Juno Therapeutics Appoints Biotech Investment Banking Leader Steve Harr As CFO And Head Of Corporate Development 3/31/2014 7:45:26 AM
Cellectis, Servier Forge Leukemia, Solid Tumors Pact To Battle With Novartis AG (NVS) And Newbie Juno Therapeutics 2/18/2014 7:39:15 AM
Already-Rich Startup, Juno Therapeutics, Expands Series A Funding Round To $145 Million 1/14/2014 7:39:08 AM
Biotech Startup, Juno Therapeutics, Grabs $120 Million To Coax Immune System To Fight Cancer 12/4/2013 7:35:09 AM